[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15123
1. Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang YH, Langer R, Sawicki JA, Anderson DG: Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s. Mol Ther; 2007 Jul;15(7):1306-1312

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, intraperitoneal (IP) gene delivery using end-modified C32 polymers resulted in expression levels over one order of magnitude higher than unmodified C32 and jet-polyethylenimine (jet-PEI) levels in several abdominal organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182918.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Wang ZY, Sun LW, Wu JL, Li L, Ma JM, Hu JD: Management of Malignant Gastric Outlet Obstruction with Expandable Metallic Stent Placement. Gastroenterology Res; 2008 Dec;1(1):40-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Malignant Gastric Outlet Obstruction with Expandable Metallic Stent Placement.
  • BACKGROUND: To investigate the efficacy and procedural skills of metallic stent placement for malignant gastric outlet obstruction.
  • METHODS: Nine patients with malignant gastric outlet obstruction were performed metallic stent placement.
  • The common post-procedural complications included nausea, vomiting, upper digestive tract hemorrhage and upper abdominal pain.
  • CONCLUSIONS: Expandable metallic stents placed in patients with malignant obstruction of gastric outlet effectively palliate the obstructive symptoms.
  • Technical skills play important roles in stent placement in treatment of malignant gastric outlet obstruction, and the efficacy of metallic stent placement is associated with the location of metallic stents and therapeutic indications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994705.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; efficacy / expandable metallic stent / gastric cancer / gastric outlet / obstruction / placement / technique skills
  •  go-up   go-down


3. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • The most common early complications were: macroscopic haematuria, pain in lower part of the abdomen, and transient dysuria.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


Advertisement
4. Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W: Locoregional IL-2 low dose applications for gastrointestinal tumors. World J Gastroenterol; 2005 Sep 21;11(35):5525-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer.
  • CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222748.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Recombinant Proteins; M89N0Q7EQR / aldesleukin
  • [Other-IDs] NLM/ PMC4320365
  •  go-up   go-down


5. Mercadante S, Villari P, Casuccio A, Marrazzo A: A randomized-controlled study of intrathecal versus epidural thoracic analgesia in patients undergoing abdominal cancer surgery. J Clin Monit Comput; 2008 Aug;22(4):293-8
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized-controlled study of intrathecal versus epidural thoracic analgesia in patients undergoing abdominal cancer surgery.
  • BACKGROUND: We sought to determine the effectiveness of continuous intrathecal thoracic analgesia (ITA) in comparison with continuous epidural thoracic analgesia (ETA) for the management of postoperative pain after abdominal cancer surgery in a randomised controlled study.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Analgesia, Epidural / methods. Injections, Spinal / methods. Lidocaine / administration & dosage. Pain Measurement / drug effects. Pain, Postoperative / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685961.001).
  • [ISSN] 1387-1307
  • [Journal-full-title] Journal of clinical monitoring and computing
  • [ISO-abbreviation] J Clin Monit Comput
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anesthetics, Local; 98PI200987 / Lidocaine
  •  go-up   go-down


6. Dravid RM, Paul RE: Interpleural block - part 2. Anaesthesia; 2007 Nov;62(11):1143-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpleural blockade is effective in treating unilateral surgical and non-surgical pain from the chest and upper abdomen in both the acute and chronic settings.
  • It has also been used successfully in the treatment of pain from multiple rib fractures, herpes zoster, complex regional pain syndromes, thoracic and abdominal cancer, and pancreatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anaesthesia. 2008 May;63(5):553 [18412662.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):551; author reply 551-2 [18412659.001]
  • [CommentIn] Anaesthesia. 2014 Jan;69(1):86-7 [24320865.001]
  • [CommentIn] Anaesthesia. 2014 Jan;69(1):85-6 [24320864.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):552-3; author reply 553 [18412660.001]
  • (PMID = 17924896.001).
  • [ISSN] 0003-2409
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Local
  • [Number-of-references] 110
  •  go-up   go-down


7. Sugita R, Ito K, Fujita N, Takahashi S: Diffusion-weighted MRI in abdominal oncology: clinical applications. World J Gastroenterol; 2010 Feb 21;16(7):832-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI in abdominal oncology: clinical applications.
  • As a result, many reports have been published on the use of DWI in abdominal diseases.
  • Particularly, abdominal DWI has now being focused on evaluation of patients with abdominal cancer.
  • DWI can be used for pretreatment tumor detection, characterization including predicting tumor response to therapy, monitoring tumor response during therapy, and follow-up study after treatment to detect possible tumor recurrence.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2000 Jun;43(6):828-36 [10861877.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):307-8 [12147376.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Feb;22(2):366-72 [11156785.001]
  • [Cites] Abdom Imaging. 2001 Mar-Apr;26(2):161-5 [11178693.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):302-7 [11891975.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):906-12 [12063214.001]
  • [Cites] Radiology. 2002 Dec;225(3):889-94 [12461275.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):958-65 [12829130.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):708-10 [12933464.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):641-9 [14628131.001]
  • [Cites] Eur Radiol. 2004 Jun;14(6):959-63 [14767604.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):136-42 [15140402.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Radiology. 1998 May;207(2):349-56 [9577479.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1457-66 [9815831.001]
  • [Cites] Radiology. 1999 Mar;210(3):617-23 [10207458.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):71-8 [15538578.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Radiology. 2005 Mar;234(3):756-64 [15734932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9 [15805192.001]
  • [Cites] Radiology. 2005 Nov;237(2):492-9 [16192323.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17(3):505-12 [16567675.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Radiology. 2006 May;239(2):448-56 [16569781.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jul;187(1):181-4 [16794174.001]
  • [Cites] J Vasc Interv Radiol. 2006 Jul;17(7):1195-200 [16868174.001]
  • [Cites] Radiology. 2006 Dec;241(3):839-46 [17032910.001]
  • [Cites] AJR Am J Roentgenol. 2007 Feb;188(2):409-14 [17242249.001]
  • [Cites] J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56 [17296704.001]
  • [Cites] AJR Am J Roentgenol. 2007 Apr;188(4):1001-8 [17377036.001]
  • [Cites] Radiology. 2007 May;243(2):493-9 [17356177.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1622-35 [17515386.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4104-9 [17827460.001]
  • [Cites] J Magn Reson Imaging. 2007 Oct;26(4):1139-44 [17896396.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1003-11 [18084607.001]
  • [Cites] Eur Radiol. 2008 May;18(5):903-10 [18193234.001]
  • [Cites] Eur Radiol. 2008 Sep;18(9):1937-52 [18446344.001]
  • [Cites] Radiology. 2008 Sep;248(3):894-900 [18710982.001]
  • [Cites] Neoplasia. 2009 Feb;11(2):102-25 [19186405.001]
  • [Cites] Eur Radiol. 2009 Jul;19(7):1794-8 [19190910.001]
  • [Cites] Eur Radiol. 2009 Aug;19(8):2024-32 [19277675.001]
  • [Cites] Radiology. 2000 Nov;217(2):331-45 [11058626.001]
  • (PMID = 20143461.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC2825329
  •  go-up   go-down


8. Dravid RM, Paul RE: Interpleural block - part 1. Anaesthesia; 2007 Oct;62(10):1039-49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpleural blockade is effective in treating unilateral surgical and nonsurgical pain from the chest and upper abdomen in both the acute and chronic settings.
  • It has also been used successfully in the treatment of pain from multiple rib fractures, herpes zoster, complex regional pain syndromes, thoracic and abdominal cancer, and pancreatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anaesthesia. 2008 May;63(5):551; author reply 551-2 [18412659.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):552-3; author reply 553 [18412660.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):553 [18412662.001]
  • [ErratumIn] Anaesthesia. 2007 Nov;62(11):1197
  • (PMID = 17845657.001).
  • [ISSN] 0003-2409
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Local
  • [Number-of-references] 73
  •  go-up   go-down


9. McDermott S, Skehan SJ: Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging; 2010 Feb;35(1):55-69
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT.
  • Proper interpretation of PET-CT images requires knowledge of the normal physiological distribution of the tracer, frequently encountered physiological variants, and benign pathological causes of FDG uptake that can be confused with a malignant neoplasm.
  • In addition, not all malignant processes are associated with avid tracer uptake.
  • This article reviews these potential pitfalls as they apply to the abdomen and pelvis of patients with cancer.
  • [MeSH-major] Abdominal Neoplasms / radiography. Abdominal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130117.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 30
  •  go-up   go-down


10. Gnanasambandam S, Olsen ØE: CT in children with abdominal cancer: should we routinely include the pelvis? Pediatr Radiol; 2006 Mar;36(3):213-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT in children with abdominal cancer: should we routinely include the pelvis?
  • BACKGROUND: It has been suggested that the pelvis should not be habitually included on abdominal CT examinations, but the potential benefit of such a practice in childhood abdominal malignancies is unknown.
  • OBJECTIVE: To estimate the yield and potential diagnostic benefit of abnormal findings on CT of the pelvis in children with malignant primary tumours in the upper abdomen.
  • MATERIALS AND METHODS: From a paediatric tertiary referral hospital we retrospectively included patients having abdominal CT for primary upper abdominal tumours (1997-2004), the scan range routinely including the pelvis.
  • CONCLUSIONS: Our data suggest that diagnostically significant findings in the pelvis are rare; consequently, the habitual inclusion of the pelvis on abdominal CT for primary malignant tumours in the abdomen is not justified.
  • [MeSH-major] Abdominal Neoplasms / radiography. Pelvis / radiography. Radiography, Abdominal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331450.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Hillbrand M, Georg D, Gadner H, Pötter R, Dieckmann K: Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy. Radiother Oncol; 2008 Nov;89(2):141-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy.
  • PURPOSE: Evaluation of dosimetric benefits of advanced radiotherapy techniques for the treatment of abdominal lesions during early childhood.
  • PATIENTS AND METHODS: Treatment planning was performed for five Neuroblastoma (NBL) and four Wilms Tumor (WT) patients.
  • The risk for radiation-induced secondary cancer was doubled for IMXT and even more increased for PT if secondary neutrons were taken into account, while this risk remained the same or was reduced by IMPT with respect to 2F.
  • Further research is needed to minimize uncertainties for secondary cancer estimations.
  • [MeSH-major] Abdominal Neoplasms / radiotherapy. Kidney Neoplasms / radiotherapy. Neuroblastoma / radiotherapy. Wilms Tumor / radiotherapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692928.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


12. Levy MJ, Wiersema MJ: Endoscopic ultrasound-guided pain control for intra-abdominal cancer. Gastroenterol Clin North Am; 2006 Mar;35(1):153-65, x
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided pain control for intra-abdominal cancer.
  • [MeSH-major] Abdominal Neoplasms / complications. Analgesia / methods. Autonomic Denervation / methods. Celiac Plexus / ultrasonography. Endoscopy. Pain / etiology. Pain Management

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530118.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


13. Park MS, Kim MJ, Lim JS, Kim SH, Kim HS, Chung YE, Kim KW: Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging. J Comput Assist Tomogr; 2009 Jan-Feb;33(1):119-24
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging.
  • MATERIALS AND METHODS: Gadobenate dimeglumine-enhanced MRI conducted in 38 patients (lesions of 43 metastases and 33 FEIs) with extrahepatic abdominal carcinoma were reviewed retrospectively.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Eosinophilia / diagnosis. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Meglumine / analogs & derivatives. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188798.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


14. McDermott A: Starting out-It was a privilege to meet the cultural needs of dying patient. Nurs Stand; 2010 Nov 03;25(9):29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had breast cancer with metastasis, and had been admitted to the acute medical ward with abdominal pain, vomiting and breathlessness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026442.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Senkal M, Haaker R, Linseisen J, Wolfram G, Homann HH, Stehle P: Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue. JPEN J Parenter Enteral Nutr; 2005;29(4):236-240

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue.
  • BACKGROUND: The uptake of ω-3 polyunsaturated fatty acids (PUFAs) into the liver, gut mucosa, and tumor tissue and plasma levels after preoperative administration of supplemented enteral nutrition was investigated in patients with malignancies of the upper gastrointestinal tract.
  • Tissue samples of liver, gut mucosa (small intestine), and tumor were taken during surgery and homogenized.
  • As compared with the control group, the PUFA group had significantly increased levels of EPA in liver tissue (0.4 vs 1.3 weight %), gut mucosa (0.3 vs 1.0 weight %), and tumor tissue (0.3 vs 0.8 weight %).
  • Also, the DHA levels in the PUFA group were significantly higher than the control group: liver tissue (4.1 vs 7.5 weight %), gut mucosa (2.1 vs 3.7 weight %) and tumor tissue (1.9 vs 4.2 weight %).
  • CONCLUSIONS: This study suggests that administration of PUFA-enriched diets leads to increased incorporation of EPA and DHA not only in liver and gut mucosa tissue, but also in tumor tissue in patients with solid gastrointestinal tumors.
  • Thus, preoperative administration of oral PUFA-enriched diets could have an impact on the postoperative inflammatory response after major abdominal surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28052736.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marcy P Sr, Chamorey E, Macchiavello J, Largillier R, Peyrade F, Ferrero J, Hanoun-Levi J, Poudenx M, François E, Frenay M: Distal or proximal venous port device insertion: Results of a prospective randomized trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility criteria included adult patients with solid tissue malignancy (neuro oncology, gynecology, lung, abdominal, head§neck) beginning a course of I.V.chemotherapy, normal hemostatic parameters, no organ failure, a life expectancy >3months, WHO status<3.
  • Exclusion criteria included current anticoagulant therapy, previous ipsilateral venous catheter/pacewires/surgical axillary node dissection/radiodermatitis, local tumor growth/sepsis, symptomatic brain metastasis, psychosis.
  • Distal (arm port) technique should be recommended in young female cancer patients (neckline cosmesis/discretion), head and neck cancer patients, obese patients (upright position) and in patients presenting with respiratory insufficiency or at high risk for pneumothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961555.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Al-Niaimi A, Manuelli B, Safdar N, Chappell R, Seo S, Kushner D, Connor J, Hartenbach E: Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience.
  • : e16515 Background: To compare the impact of surgical versus medical management on the survival of patients presenting with small bowel obstruction (SBO) secondary to recurrent ovarian cancer.
  • METHODS: The Institutional Review Board approved a retrospective chart review of all patients with SBO due to recurrent ovarian cancer at the University of Wisconsin Hospital between January 1, 1992, and December 31, 2007.
  • The data abstracted from patient charts included demographics, primary cancer characteristics, detailed clinical information at the time of SBO, management strategy, and outcome.
  • 86% of the patients had stage III/IV ovarian cancer, while 14% had stage I/II.
  • The median time from tumor recurrence to bowel obstruction was 17 months.
  • Patients without abdominal or pelvic mass on CT had a median survival of 60 months; patients with any mass noted had a median survival of 3.6 months; patients with liver and lung metastases was 3 months (p = 0.001).
  • CONCLUSIONS: In patients with bowel obstruction due to ovarian cancer recurrence; early stage at diagnosis, the absence of ascites, and lack of abdominal/pelvic mass or distant metastases significantly lengthens survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lu W, Low DA, Parikh PJ, Nystrom MM, El Naqa IM, Wahab SH, Handoko M, Fooshee D, Bradley JD: Comparison of spirometry and abdominal height as four-dimensional computed tomography metrics in lung. Med Phys; 2005 Jul;32(7Part1):2351-2357

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of spirometry and abdominal height as four-dimensional computed tomography metrics in lung.
  • This study compared two noninvasive breathing metrics, spirometry and abdominal height, against internal air content, used as a surrogate for internal motion.
  • Both metrics were shown to be accurate, but the spirometry showed a stronger and more reproducible relationship than the abdominal height in the lung.
  • The abdominal height was known to be affected by sensor placement and patient positioning while the spirometer exhibited signal drift.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493581.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed radiography / Computed tomography / Height measurements / Hemodynamics / Intensity modulated radiation therapy / Lungs / Medical imaging / Movement sensors / Pneumodyamics, respiration / Position sensitive detectors / Radiation therapy / Tissues / abdominal height / biomedical measurement / breathing motion / computerised tomography / lung / pneumodynamics / radiation therapy / spirometry
  •  go-up   go-down


19. Plotkin SR, Singh M, Cai W, O'Donnell C, Esparza S, Smith MJ, Harris GJ, Muzikansky A, Bredella MA, Kassarjian A: Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol; 2009 May 20;27(15_suppl):2074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes.
  • A rapid and sensitive method to detect internal tumors is highly desirable since they can cause neurologic dysfunction, compress vital structures, or transform into malignant tumors.
  • The number and type of tumors (discrete vs. plexiform) were identified by a board-certified radiologist and tumor volume was calculated using semi-automated analysis.
  • Sixty-one percent of subjects had ≥1 internal tumor.
  • Overall, the legs harbored the greatest number of tumors (33%), followed by the pelvis (18%), thorax (15%), abdomen (12%), arms (10%), and head/neck (7%).
  • Only 40% of internal tumors were classified as plexiform yet these tumors contributed 78% of the tumor burden by volume.
  • In addition, WBMRI may prove useful in identifying individual patients at high risk for complications (such as neurologic dysfunction or malignant transformation) due to heavy internal tumor burden and in determining the efficacy of antitumor drugs in this unique patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hariprasad R, Kumar L, Kumar S, Bhatla N, Thulkar S, Das P: Advanced epithelial ovarian cancer (EOC): Is there a place for maintenance therapy in patients with sub-optimal debulking? J Clin Oncol; 2009 May 20;27(15_suppl):e14580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced epithelial ovarian cancer (EOC): Is there a place for maintenance therapy in patients with sub-optimal debulking?
  • : e14580 Background: Survival of patients with advanced epithelial ovarian cancer (EOC) with initial suboptimal debulking surgery (residual disease (>1 cm) and those with recurrent EOC is poor.
  • Serum CA-125 was done once in 2 months and CAT scan of abdomen & pelvis every 6 month.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ito Y, Hatake K, Takahashi S, Yokoyama M, Suenaga M, Ota M, Onozawa Y, Yamazaki K, Hironaka S, Boku N: Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor measurements were made at screening and at the end of every 8 weeks (2 cycles) by RECIST.
  • Tumor types at primary diagnosis were advanced colorectal (81%), breast (14%), and gastric (5%) cancer.
  • Neratinib-related AEs, any grade in ≥25% of pts included diarrhea (95%), fatigue (67%), anorexia (43%), nausea (43%), abdominal pain (38%), decreased hemoglobin (38%), increased AST (33%), and rash (29%).
  • The 2 pts with PR had ErbB-2+ advanced breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, Lengyel E, Gilder K, Ho S, Schilder RJ: Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer.
  • A Phase I/II study was performed to evaluate PLD with/without V in patients (pts) with recurrent ovarian or primary peritoneal cancer that relapsed after platinum/taxane-based chemotherapy (maximum 2 prior lines).
  • The most common Grade 3/4 AEs (≥5% in any group) were abdominal pain, intestinal obstruction, ascites, fatigue, hypoalbuminemia, and cytopenias.
  • Analyses correlating PFS with platinum sensitivity and α5β1 tumor expression are ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962571.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, Civoli F, Richards D: A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).
  • : 4501 Background: AMG 655 is an investigational, fully human agonist monoclonal antibody (IgG1) that binds human death receptor 5 (DR5), activates caspases, and induces apoptosis in sensitive tumor cells.
  • Nine (69%) pts had grade 3-4 toxicity, the most common were: thrombocytopenia (4 pts), neutropenia (2 pts), and abdominal pain (2 pts).
  • CONCLUSIONS: AMG 655 + G is well-tolerated and may have activity in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Stearns V, Jacobs LK, Tsangaris TN, Briest S, Lange JR, Slater S, Fackler M, Sugar E, Gabrielson E, Davidson NE: A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer.
  • : e14508 Background: Epigenetic modifications contribute to breast cancer initiation and progression and may be reversible, thus representing an attractive area for new drug investigation.
  • In preclinical breast cancer models, the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) induces cell cycle arrest, apoptosis and differentiation.
  • Baseline and post-treatment tumor specimens were collected for analysis of histone acetylation, candidate gene methylation and expression.
  • One participant took 4 and one 5 doses due to insurance clearance delay; one received a single dose due to fatigue and abdominal pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pua T, Novetsky AP, Blank SV: Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients.
  • Epithelial ovarian cancer (EOC) and cirrhosis share manifestations of increased abdominal girth, ascites, malnutrition and abnormal laboratory findings.
  • Of note there were 4 peri-operative deaths, all in the B/C group (p = 0.01).
  • CONCLUSIONS: Application of the Child classification to women with ovarian cancer revealed increased rates of suboptimal cytoreduction and peri-operative complications including ICU admission, infection, transfusion and death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Jimeno A, Hong DS, Hecker S, Clement R, Kurzrock R, Pestano LA, Hiscox A, Leos RA, Kirkpatrick DL, Eckhardt SG, Herbst RS: Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):3542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PX-866 is being evaluated in a phase 1 clinical trial to determine the MTD, and measure safety, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in PBMCs and tumor tissue in patients with solid tumors.
  • METHODS: Patients with advanced metastatic cancers receive PX-866 orally once daily for 5 of 7 days for 2 weeks in a 28-day cycle.
  • Once the MTD of this PX-866 schedule of administration has been identified, an expansion cohort is planned to investigate tumor PD events and correlate tumor and PBMC endpoints with efficacy.
  • Abdominal discomfort and mild diarrhea have been possibly associated with PX-866.
  • Two patients (squamous cell skin cancer and melanoma) had decrease in pain allowing discontinuation of analgesics.
  • PX-866 has shown to have a mild side effect profile while inducing stabilization of disease in previously progressing cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961356.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Blackstock AW, Aklilu M, Lovato J, Degrass L, Sommer J, Howerton R, Mishra G, Levine E, McQuellon R: Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/ 5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/ 5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer.
  • : e20661 Background: Significant chemoradiation-induced nausea and vomiting (CRINV) occurs in patients (pts) receiving chemoradiation for pancreatic cancer.
  • METHODS: Pts with locally advanced or resected pancreatic cancer received wkly Gemcitabine (200 mg/m2) and continuous infusion 5-fluorouracil (5-FU) or oral capecitabine with concurrent radiation (50.4 Gy).
  • The Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) questionnaire was completed at baseline prior to the start of all therapy, Time 1 (T#1), repeated at the end of the first week (T#2) and then repeated again at the end of the last full week of chemoradiation (T#3).
  • CONCLUSIONS: Prophylactic Aprepitant/5HT-3/dexamethasone therapy resulted in minimal CRINV for pts receiving upper abdominal chemoradiation in this feasibility study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Giles FJ, O'Brien S, Rizzieri DA, Vey N, Krug U, Sekeres M, Jacobsen TF, Nilsson BI, Staudacher K: A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol; 2009 May 20;27(15_suppl):7047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequently reported related AE ≥ grade 3 (CTCAE v3.0) were myelosuppression, abdominal pain, colitis, diarrhoea, nausea, fatigue, liver function test (LFT) elevation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shankar V, Haritha C, Trivedi HL, Vanikar A, Modi PM, Shah P, Shah V: Radiation dose-benefit analysis of hematopoietic stem cell grafting for tolerence induction across MHC barriers in living related donor renal allograft recipients. J Clin Oncol; 2009 May 20;27(15_suppl):3044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent subtotal lymphoid irradiation (STLI) targeting spleen, abdominal, iliac and inguinal lymph nodes, thoraco-lumbar vertebra and 75% of pelvis.
  • Tolerance - Robust (R), Prope (P) and Metastable (M) is defined as RT: Stable allograft function (fn.) for >100 days without ISp; PT: Early adequate, stable grafts fn. with no rejection episodes on minimum ISp; MT: Adequate graft fn. on ISp with single episode of steroid responsive ac. rejection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Hurwitz H, Patt YZ, Henry D, Garbo L, Mitchell EP, Kohles J, Spigel D: Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis.
  • Complete surgical resection was allowed using pre-defined criteria.
  • Other grade 3/4 toxicities (>5%, Q2W vs Q3W) included fatigue (13% vs 13%), dehydration (12% vs 10%), nausea (8% vs 9%), peripheral neuropathy (5% vs 9%), anorexia (5% vs 7%), and abdominal pain (5% vs 7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961632.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Laheru D, Rudek M, Taylor G, Goldsweig H, Rajeshkumar NV, Linden S, Angenendt M, Le D, Donehower R, Jimeno A, Hidalgo M: Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer.
  • : 4529 Background: The Ras signaling pathway stands as a strategic target in pancreatic cancer.
  • Here we studied the activity of this agent in patients with advanced pancreatic cancer.
  • METHODS: Patients with treatment naïve advanced peri-ampullary cancer were treated with gemcitabine (Gem) administered at standard dose and schedule + FTS administered orally at doses of 200-800 mg bid 21 days of a 28 day cycle.
  • Patients were treated until progression or protocol defined DLT.
  • The most common adverse events were neutropenia, anemia, abdominal cramping, elevated liver function tests and diarrhea.
  • 4. Salirasib mechanism of Ras inhibition is confirmed by reduction of tumor Ras in pancreatic cancer patients.
  • 5. Salirasib warrants evaluation in a controlled study with gemcitabine in pancreatic cancer; doses of 600 or 400 mg b.i.d. are recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Saglam S, Bugra D, Kaytan Saglam E, Yamaner S, Asoglu O, Balik E, Oral EN, Sakar B, Kizir A, Kapran Y, Camlica H: Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3-4/N0+ rectal cancer: Istanbul R-01 Study. J Clin Oncol; 2009 May 20;27(15_suppl):4131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3-4/N0+ rectal cancer: Istanbul R-01 Study.
  • : 4131 Background: Prospective randomized study has been designed to compare the efficacy of fourth week surgery (4WS) versus eighth week surgery (8WS) after concomitant neoadjuvant chemoradiotherapy (NeoadjCTRT) on local recurrence and overall survival (OS) in cT3-4/N0+, mid and distal localized (intraperitoneal) rectal cancers.
  • All rectal cancer pts are T3-4/N0+; distal and mid rectum and received 45 Gy conventionally fractionated RT in 25 daily fractions of 1.8 Gy combined with 225 mg/m<sup>2</sup>/day continous infusion 5-FU.
  • Preoperative staging was performed by endorectal USG and /or MRI and abdominal CT.4cycles FUFA is standard as adjuvant treatment after surgery.
  • Important factors for local recurrence and (OS) are having distal rectal tumor and SMP and <2mm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960838.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Phase 2 Consortium: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  • : 3521 Background: Systemic therapies have had little impact on the outcomes of patients with advanced differentiated thyroid cancers.
  • METHODS: A three-outcome one-stage Phase II trial was conducted to assess the anti-tumor activity and toxicities of the orally bioavailable VEGF/tyrosine kinase inhibitor pazopanib (800 mg daily) in patients with advanced and progressive radioiodine-insensitive differentiated thyroid cancers.
  • Six patients (23%) required dose reduction due to: grade 2+ ALT (3 pts), grade 3 mucositis (1 pt); grade 3 diarrhea and dehydration (1 pt), and grade 3 abdominal pain (1 pt.).
  • CONCLUSIONS: Pazopanib appears to have both a favorable toxicity profile and promising clinical activity in patients with advanced and progressive differentiated thyroid cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, Li J, Su Y, Dhawan R, Kaye S: Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol; 2009 May 20;27(15_suppl):5526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
  • : 5526 Background: In an open-label, multicenter, randomized phase III study comparing the combination of trabectedin and PLD to PLD alone in patients with relapsed ovarian cancer, the combination demonstrated significantly improved progression free survival and response rates, manageable non-cumulative toxicity, and fewer PLD-associated adverse events.
  • Global health status/QoL, fatigue, rain subscales from QLQ C30, and abdominal pain/GI symptoms scale from OV28 were chosen a priori for primary analyses.
  • CONCLUSIONS: The addition of trabectedin to PLD results in superior efficacy in patients with relapsed ovarian cancer, with no added decrement to overall health status as assessed by PRO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Samelis GF, Tsiakou A, Karamanidi M, Pelechrini M, Zaganides A, Ekmektzoglou K: Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival. J Clin Oncol; 2009 May 20;27(15_suppl):e15143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival.
  • : e15143 Background: The management of patients with metastatic colorectal cancer (mCRC) has evolved dramatically over the last decade, with several "targeted" agents having entered the treatment arena.
  • METHODS: We evaluated the efficacy and safety of bevacizumab in combination with standard chemotherapy (irinotecan, capecitabine, oxaliplatin, cetuximab) in 21 patients with metastatic colorectal cancer with a median age of 69 (range: 47-85) years old with PS: 0-1, included in the study.
  • The metastatic sites were liver in 13 patients, liver and lung in 4 patients, lung in 2 patients, intra-abdominal in 1 patient and urinary-bladder in 1 patient.
  • Subgroup analysis was performed in terms of age, site of metastases, spread and co-morbidity.
  • CONCLUSIONS: Multiple line treatment in advanced colorectal cancer, including bevacizumab combined with standard chemotherapy, may improve OS (median: 23+ months) with an acceptable toxicity profile in patients with mCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC: Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol; 2009 May 20;27(15_suppl):10017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At IRN 50 mg/m<sup>2</sup>/day, 4/12 pts had DLT (hepatotoxicity, abdominal pain, anorexia, hypokalemia, and thrombocytopenia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962502.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. van der Veldt A, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E: Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. J Clin Oncol; 2009 May 20;27(15_suppl):5044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
  • : 5044 Background: Sunitinib (SU) has been approved for the treatment of metastatic renal cell cancer (mRCC).
  • Since SU can induce extensive necrosis, RECIST may be inappropriate for tumor response evaluation.
  • Imaging data consisted of thoracic and abdominal helical CT scans at baseline, after a median of 2 months and were repeated during treatment.
  • According to Choi criteria partial response (PR) was defined as ≥10% decrease in size or ≥15% decrease in density, while progressive disease (PD) was defined as ≥10% increase in size without meeting PR criteria by density.
  • RESULTS: For RECIST and Choi criteria, respectively, 230 and 156 tumor lesions were eligible.
  • The median tumor density decreased significantly (Wilcoxon Signed Ranks test, p ≤ 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Moroney JW, Coleman RL, Hong DS, Wheler JJ, Ng C, Bodurka DC, Falchook G, Naing A, Helgason T, Kurzrock R: A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):e13508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At first restaging, 2/2 patients with endometrial cancer were found to have ≥ 25% decrease in tumor size (RECIST), and one patient with colorectal carcinoma had a 15% decrease.
  • One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care.
  • CONCLUSIONS: Preliminary data indicate that the combination of D, A and T has anti-tumor activity and is well tolerated at the doses used.
  • Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • Location of the tumor: head (33 pts), body (13 pts), and tail (5 pts).
  • 30 pts experienced at least one episode of grade 3 or 4 toxicity (asthenia 12 pts, anorexia 11 pts, vomiting 10 pts, nausea 9 pts, abdominal pain 5 pts).
  • Grant by sanofi-aventis, Amgen, and Ligue Nationale Contre Le Cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Oaknin AM, Romeo M, Pons F, Perez X, Barretina P, Vidal A, Martí L, Barahona M, Germá J, Ponce J: Behavior of borderline ovarian tumours (BOTs): Single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 6 patients (7.8%) with noninvasive implants involving abdominal peritoneum (1), pelvic peritoneum (1), omentum (2) and both pelvic peritoneum and omentum (2).
  • All were stage I disease at diagnosis.
  • Histology recurrences were: 2 borderline, 2 invasive ovarian cancer, and 1 unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961533.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Olmos D, Allred A, Sharma R, Brunetto A, Smith D, Murray S, Barker D, Taegtmeyer A, de Bono J, Blagden S: Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3536 Background: Polo-like kinase-1 (Plk1), part of a family of highly conserved serine-threonine kinases, has multiple roles in mitotic progression, is over-expressed and also associated with poor prognosis in some tumor types.
  • Secondary objectives included preliminary evaluation of anti-tumor activity.
  • Other Sch 1 adverse events (AEs) with a maximum grade ≥3 were fatigue and anemia (both, n = 2), pleuritic pain, pelvic pain, abdominal discomfort, constipation, vomiting, neutropenia, and deep vein thrombosis (all, n = 1).
  • The most common adverse events (AEs) regardless of attribution, Sch and dose level were phlebitis (n = 9), fatigue (n = 9), nausea (n = 7), anemia (n = 6), anorexia (n = 6), diarrhea (n = 6), and infusion site reaction (n = 5).
  • Phospho-histone H3, a marker of mitotic arrest, was detected, in circulating tumor cells, 24 hrs after first dose.
  • Stable disease >5m has been observed in 2 esophageal cancer pts.
  • An MTD has not yet been defined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Meyniel J, Cottu PH, Stern M, Lebigot I, Mignot L, Roman-Roman S, Sastre-Garau X: A genomic and transcriptomic approach to distinguish primary and metastatic ovary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22150 Background: Distinction of primary ovarian tumors from metastatic tumors involving the ovary is in some cases challenging for final pathologic diagnosis and for treatment with efficient chemotherapy Methods: We gathered from our biobank 16 pairs of breast/ovarian tumors for some of which the diagnosis was uncertain.
  • We investigated the possibility to improve diagnosis using genomic and transcriptomic tools.
  • RESULTS: Primary infiltrating lobular carcinoma (ILC) was observed in 6 patients, infiltrating ductal carcinoma (IDC) in 7 patients, 1 patient had one ILC and one IDC, 1 patient had a mixed IDC+ILC and 1 patient an undifferentiated cancer.
  • Median time to diagnosis of ovarian tumor was 54 months.
  • Ovarian tumors were considered as primary in 7 patients, and metastatic in 9 patients, and diagnosis was ambiguous in 4 of them.
  • Four patients developed extra-abdominal metastases.
  • Median survival from breast cancer diagnosis was 78 months, and from ovarian tumor diagnosis was 29 months.
  • In 4 cases, the genomic profiles established clearly the status of the ovary tumor whereas the pathological analysis did not.
  • CONCLUSIONS: We clearly established in this training series that CGH array analysis could help to discriminate between primary and secondary ovarian tumors from breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963541.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Guida M, Porcelli G, Ruggieri E, Zito A, Mattioli V, Montemurro S, Colucci G: Electrochemoterapy (ECT) for the treatment of superficial tumor localizations. J Clin Oncol; 2009 May 20;27(15_suppl):e13526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemoterapy (ECT) for the treatment of superficial tumor localizations.
  • : e13526 Background: ECT is an effective local treatment for palliation on inoperable superficial neoplastic lesions from any type of tumour.
  • METHODS: We treated 26 pts, M/F 12/14; median age 61 yrs, range 38-87: 7 breast cancer with nodular or infiltrating lesions in thoracic or abdominal wall; 12 melanoma (2 wide infiltration of thoracic wall, 10 in transit metastases or loco-regional recurrences); 2 head-neck cancer with a wide neck-scalp infiltration; 3 lymphomas with cutaneous lesions, 1 soft tissue sarcoma with a subcutaneous recurrence, 1 gastric cancer with 2 cutaneous localizations.
  • Intravenous bleomycin (15 mg/m<sup>2</sup>) were used in all patient; electric pulses were than applied to the tumor areas by needle electrodes in a time window of 20 minutes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Somlo G, Atzori F, Strauss L, Rybicki A, Wu X, Gradishar W, Specht J: Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. J Clin Oncol; 2009 May 20;27(15_suppl):1012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004.
  • : 1012 Background: SRC family kinases (SFK) mediate numerous signal-transduction pathways relevant to breast cancer as well as osteoclast function.
  • Dasatinib, a potent oral inhibitor of SFK and other kinases has preclinical activity in breast models and in vitro synergy with Cap in some breast cancer cell lines (KPL-4 and HCC-70).
  • Most frequent AEs related to either drug and occurring at any time on study (n pts) were nausea (12), vomiting (7), diarrhea (6), abdominal pain (2), fatigue (8), headache (7), musculoskeletal pain (1), and pleural effusion (4); hand-foot syndrome (5) was as expected for Cap alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960743.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Surgery (performed in 14 patients) consisted of low anterior resection in 5pts and abdominal-perineal resection in 10p.
  • Tumor down-staging was observed in 10pts (66.6%), including 5pts with complete pathological response (33.3%).
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Gardner K, Judson I, Leahy M, Barquin E, Marotti M, Collins B, Young H, Scurr M: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response to conventional chemotherapy is poor (overall response rates are approximately 7% [Reichardt P et al,Eur J Cancer.2003;39:1511-1516]).
  • RESULTS: Median age at diagnosis was 39 years (range: 26-49).
  • All patients had pulmonary metastases and two had additional sites of disease (brain, bone, intra-abdominal) at study entry.
  • Four patients had a best response of partial response, two patients had a confirmed reduction in maximum tumor diameter of ≥10% and <30% and one patient experienced stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Camargo VP, Maki RG: Clinical outcomes of systemic therapy for patients with desmoids. J Clin Oncol; 2009 May 20;27(15_suppl):10585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-abdominal primary location was most common (29/70=41%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL).
  • : e15114 Background: In a previous study, IFL was used in patients (pt) with untreated metastatic colon cancer and a median overall survival (MOS) of 31 months (m).
  • In the current study we added B to IFL to determine toxicity profiles (TP) and the response rate (RR) to the B-IFL regimen.
  • Eligible pt received 2 cycles of B-IFL followed by CT scan.
  • 8 pt (36%) had bilobar liver disease and involvement of 1 other organ, 6 pt (27%) had bilobar liver disease with involvement of ≥ 2 other organs; 5 pt (23.5%) had bilobar liver disease; 2 pt (9%) had abdominal carcinomatosis; 1 pt (4.5 %) had involvement in one liver lobe.
  • Gr 3 occurred in 11 pt (50%); DVT, diarrhea (Drh) 3 pt (14%); fatigue (Ftg), infection, port site thrombosis (Pst), small bowel obstruction 2 pt (9%); wound dehiscence 1pt (5%); Gr 2 and 1: constipation; Drh; Ftg; nausea; neutropenia; Pst; alopecia; anorexia; mucositis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Sakon M, Ikeda M: Venous thromboembolism in abdominal cancer surgery. Clin J Gastroenterol; 2009 Aug;2(4):247-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in abdominal cancer surgery.
  • Cancer, particularly adenocarcinoma developing in the digestive organs, is one of the most potent risk factors for VTE, as first described by Trousseau in 1865.
  • Cell membrane microparticles shedding from cancer cells play a critical role in venous clot formation through tissue factor (TF)-mediated activation of the coagulation system.
  • Since recent prospective studies have demonstrated that VTE risk in Japanese surgical patients is comparable to that in Caucasians, perioperative thromboprophylaxis with anticoagulants is now considered essential in patients undergoing abdominal cancer surgery, in addition to mechanical thromboprophylaxis.
  • Recent multi-center studies have also shown the efficacy and safety of enoxaparin, a low molecular weight heparin (LMWH), and fondaparinux, a synthetic Xa inhibitor, in VTE prevention after abdominal cancer surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26192418.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Digestive cancer / Thromboprophylaxis / Venous thromboembolism
  •  go-up   go-down


50. Watkins WT, Li R, Lewis J, Park JC, Sandhu A, Jiang SB, Song WY: Patient-specific motion artifacts in 4DCT. Med Phys; 2010 Jun;37(6Part1):2855-2861

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Four-dimensional computed tomography (4DCT) has enhanced images of the thorax and upper abdomen during respiration, but intraphase residual motion artifacts will persist in cine-mode scanning.
  • It was determined that these motion artifacts depend on patient-specific tumor motion and CT gantry rotation speed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512952.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4DCT / Cancer / Computed tomography / Image sensors / Lungs / Medical image artifacts / Medical image reconstruction / Medical imaging / Pneumodyamics, respiration / Pneumodynamics / Radiation therapy / Reconstruction / Time resolved imaging / X-ray imaging / biological organs / cancer / computerised tomography / image motion analysis / image reconstruction / intrafraction motion / lung / lung cancer / medical image processing / patient-specific margin / phantoms / pneumodynamics / tumours / uncertainty
  •  go-up   go-down


51. Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, Senzer N: Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3548 Background: ARQ 197 is a selective, non-ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.
  • RESULTS: To date, 65 pts (38 male/27 female; median age 61; 9 colon/colorectal, 8 renal cell carcinoma/kidney, 6 ovarian, 6 sarcoma, 5 lung cancer and 31 others) have been treated at 11 dose levels (10 mg bid to 360 mg bid).
  • One case each of the following drug-related serious AEs were reported in 4 pts: anemia, leukopenia, neutropenia, thrombocytopenia, dehydration, liver failure, abdominal pain, nausea, and vomiting.
  • Three pts with neuroendocrine, prostate, or testicular cancer achieved a partial response (PR), 32 demonstrated stable disease (SD) and 13 progressed.
  • Preliminary evidence of anti-cancer activity was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961350.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Konner JA, Grabon D, Pezzulli S, Iasonos A, Sabbatini P, Hensley M, Bell-McGuinn K, Tew W, Spriggs D, Aghajanian C: A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer.
  • : 5539 Background: IP cisplatin (Cis) plus IV/IP paclitaxel (Tax) is a standard therapy for optimally debulked ovarian cancer.
  • Activity of Bev in recurrent ovarian cancer has been reported in phase II trials.
  • METHODS: Patients with optimal (<1 cm residual), FIGO stage II or III, epithelial ovarian, fallopian tube, or peritoneal cancer, acceptable organ function, and KPS ≥ 70% are eligible.
  • There were 3 occurrences of grade 3 abdominal pain (8%); and 3 adhesion-related grade 3 small bowel obstructions (8%), during cycles 3, 9, and 15, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D: Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preclinical studies have shown synergistic antitumor activity with the combination of trastuzumab plus vinorelbine in metastatic breast cancer.The recommended dose of neratinib in monotherapy is 240 mg.
  • Tumor measurements were made every 6 wks by modified RECIST criteria.
  • AEs, any causality, all grades in ≥ 15% of pts included diarrhea (92%), nausea (67%), constipation (50%), fatigue (42%), vomiting and anthralgia (33% each), abdominal pain and anorexia, (25% each), anemia and neutropenia (17% each).
  • Preliminary efficacy data show that 1 pt with stomach cancer had stable disease, lasting ≥21 weeks.
  • CONCLUSIONS: The combination of 240 mg neratinib and 25 mg/m<sup>2</sup> vinorelbine was found to be tolerable and to demonstrate early evidence of clinical benefit in pts with solid tumors, to be assessed further in pts with metastatic ErbB-2+ breast cancer in part 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Walji N, Zachariah A, Yap C, Hussain SA, Poole CJ, El-Modir A, Ganesan R, Fernando IN: Carboplatin, ifosfamide, and mesna (CIM) for the treatment of gynecological carcinosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16539 Background: A GOG trial comparing cisplatin/ifosfamide/mesna chemotherapy versus whole abdominal irradiation for FIGO stages I-IV carcinosarcoma (CS) showed an estimated median survival (MS) of 50 months for chemotherapy but high toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Gerber B, Stehle H, Ricardo F, Maass N, Fischer D, Sommer HL, Conrad B, Mehta K, Loibl S: ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol; 2009 May 20;27(15_suppl):526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37).
  • To prevent related health problems and to maintain fertility after chemotherapy in patients with hormone insensitive breast cancer, ovarian function might be protected by using a GnRH-agonist.
  • METHODS: Patients (pts) < 46 years, with a hormone insensitive breast cancer were randomized to receive an anthracycline/taxane containing chemotherapy with or without goserelin 3.6mg in parallel as subcutaneous injection in the abdominal wall starting at least 2 weeks before chemotherapy, and thereafter every 4 weeks (28 ± 3 days) until the end of the last chemotherapy cycle (EOC).
  • The endpoint normal ovarian function 6 months after EOC is defined by two consecutive menstrual periods within 21-35 days within a time frame of 5-8 months after last application of goserelin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • Surgery (performed in 14 patients) consisted of low anterior resection in 7pts and abdominal-perineal resection in 8pts.
  • Tumor down staging was observed in 9pts (60%), including 5pts with complete pathological response (33.3%).
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • All patients underwent exploratory laparotomy, cytology, total abdominal hysterectomy and bilateral salpingoophorectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Gujral K, Petryk A, Steffen L, Baker K, Perkins J, Kelly AS, Zhou X, Sinaiko A, Moran A, Steinberger J: Growth hormone deficiency and cardiovascular risk factors in childhood cancer survivors. J Clin Oncol; 2009 May 20;27(15_suppl):6614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone deficiency and cardiovascular risk factors in childhood cancer survivors.
  • : 6614 Background: Childhood cancer survivors (CCS) have a high frequency of growth hormone deficiency (GHD) and risk of early cardiovascular disease (CVD).
  • METHODS: Anthropometrics, blood pressure, lipids, growth hormone (GH) stimulation test, dual-energy x-ray absorptiometry, abdominal CT, and insulin resistance (IR) (euglycemic, hyperinsulinemic clamp - low M/lbm signifies IR) were obtained in 174 CCS, mean age 15±2 years and 89 healthy sibling controls, mean age 13.5±3 years.
  • These study findings imply that CVD risk factors are present in CCS with GHD independent of body fatness, suggesting that the cancer diagnosis or treatments received may lead to early cardiovascular disease in childhood cancer survivors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961768.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Zhang Q, Hu YC, Liu F, Goodman K, Rosenzweig KE, Mageras GS: Correction of motion artifacts in cone-beam CT using a patient-specific respiratory motion model. Med Phys; 2010 Jun;37(6Part1):2901-2909

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Motion correction methods in CBCT have focused on the thorax because of its higher soft tissue contrast, whereas low-contrast tissue in abdomen remains a challenge.
  • The authors report on a method to correct respiration-induced motion artifacts in 1 min CBCT scans that is applicable in both thorax and abdomen, using a motion model adapted to the patient from a respiration-correlated image set.
  • In the thorax, the model is obtained from the same CBCT images that are to be motion-corrected, whereas in the abdomen, the model uses respiration-correlated CT (RCCT) images acquired prior to the treatment session.
  • The approximately 600 projection images are sorted into six (in thorax) or ten (in abdomen) subsets and reconstructed to obtain a set of low-quality respiration-correlated RC-CBCT images.
  • Repeated application of the model with different reference images produces a series of motion-corrected CBCT images over the respiration cycle, for determining the motion extent of the tumor and nearby organs at risk.
  • RESULTS: Evaluation in lung phantom, two patient cases in thorax and two in upper abdomen, shows that blurring and streaking artifacts are visibly reduced with motion correction.
  • Repeat application of the method in one thorax case, with reference images chosen at end expiration and end inspiration, indicates its feasibility for observing tumor motion extent.
  • CONCLUSIONS: Motion correction of CBCT is feasible and yields observable improvement in the thorax and abdomen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512947.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Calibration / Cancer / Computed tomography / Cone beam computed tomography / Eigenvalues / Lungs / Medical image artifacts / Medical imaging / Pneumodyamics, respiration / Reconstruction / Registration / Tissues / computerised tomography / cone-beam computed tomography / image reconstruction / image registration / image-guided radiation treatment / kidney / liver cancer / lung / lung cancer / medical image processing / organ motion / pneumodynamics / principal component analysis / tumours
  •  go-up   go-down


60. Tew WP, O'Cearbhaill R, Zhou Q, Thaler H, Konner J, Hensley ML, Sabbatini P, Spriggs D, Aghajanian C, Lichtman SM: Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC). J Clin Oncol; 2009 May 20;27(15_suppl):5541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC).
  • Toxicities included: 32% had IP port complications, 42% functional decline, 43% new ≥ Gr1 neuropathy (4% Gr3), 12% Gr2 hearing impairment, 60% ≥ Gr1 nausea/vomiting (4% Gr3), 57% ≥ Gr1 diarrhea/constipation (0% Gr3), 37% ≥ Gr1 abdominal pain (2% Gr3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Brock KK, Sharpe MB, Dawson LA, Kim SM, Jaffray DA: Accuracy of finite element model-based multi-organ deformable image registration. Med Phys; 2005 Jun;32(6Part1):1647-1659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The feasibility and accuracy of the method was tested on MR thoracic and abdominal images of healthy volunteers at inhale and exhale.
  • For the abdominal cases, the liver, spleen, and external surface were explicitly deformed and the stomach and kidneys were implicitly deformed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513963.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Bifurcations / Cancer / Clinical applications / Field emitters / Finite element methods / Finite-element and Galerkin methods / Hemodynamics / Image analysis / Image registration / Liver / Lungs / Materials properties / Mechanical and electrical properties of tissues and organs / Medical imaging / Pneumodyamics, respiration / biomechanics / biomedical MRI / finite element analysis / image registration / kidney / liver / lung / medical image processing / pneumodynamics
  •  go-up   go-down


62. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • A total of 7 patients had postoperative complications such as continuous pancreatic juice secretion (13.8%), abdominal abscess (10.3%), leakage of the anastomosis (3.4%), and pulmonary insufficiency (10.3%).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine.
  • 4 abdominal pain, 1 p. gr.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. McMeekin DD, Lanneau G, Curiel J, Moore K, Walker J, Mannel R: Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. J Clin Oncol; 2009 May 20;27(15_suppl):5540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers.
  • : 5540 Background: Excessive toxicity and difficulty in completing prescribed cycles are cited as factors behind the lack of routine acceptance of IP therapy in O/P cancer.
  • METHODS: An open label phase II study was conducted in patients (pts) with stage II-III O/P cancers with residual disease < 1 cm.
  • Of 20 evaluable pts, 2 pts discontinued prematurely (1 after cycle 1 due to elevated liver function tests, 1 after cycle 4 due to grade 3 neuropathy), and 1 pt received cycle 6 by IV route secondary to abdominal pain with IP infusion.
  • One patient developed a DVT, one had an intra-abdominal fistula requiring surgical intervention after cycle 6.
  • CONCLUSIONS: The addition of bevacizumab to an IP regimen for O/P cancers did not add to enhanced acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Nobes JP, Langley SE, Laing RW: Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer.
  • : 5159 Background: The association between androgen deprivation therapy (ADT) for prostate cancer and metabolic syndrome has been reported, with insulin resistance as the key to its development.
  • METHODS: Forty men with any stage of prostate cancer, due to receive ADT with a GnRH agonist, were recruited to a prospective randomised pilot study.
  • Men in the intervention arm (n=20) received ADT with 6 months of metformin, a low glycaemic index diet and a regular aerobic exercise programme.
  • The table shows an improvement in abdominal girth, weight, body mass index, and systolic blood pressure in the intervention arm, when measured as a % change over 6 months.
  • CONCLUSIONS: ADT is widely used in prostate cancer, but metabolic complications may be responsible for an increased cardiovascular mortality.
  • However, the anticipated increased incidence of insulin resistance and metabolic syndrome has not been demonstrated in men receiving ADT alone, which may be due to small study size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Tsujinaka T, Hirao M, Fujitani K, Mishima H, Ikenaga M, Sawamura T, Kurata M: Effect of preoperative immunonutrition on body composition in patients undergoing abdominal cancer surgery. Surg Today; 2007;37(2):118-21
MedlinePlus Health Information. consumer health - Dietary Proteins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative immunonutrition on body composition in patients undergoing abdominal cancer surgery.
  • PURPOSE: Preoperative immunonutrition may induce changes that modulate stress responses and improve the outcome of patients undergoing abdominal cancer surgery.
  • METHODS: Forty patients aged 20-75 years, who were scheduled to undergo abdominal cancer surgery, were given Impact for 5 days preoperatively, at 1000 ml/day, in addition to a regular diet.
  • CONCLUSIONS: Preoperative immunonutrition was well tolerated by cancer patients.
  • [MeSH-major] Abdominal Neoplasms / diet therapy. Abdominal Neoplasms / surgery. Body Composition / physiology. Dietary Proteins / administration & dosage. Immunotherapy / methods. Preoperative Care / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243029.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dietary Proteins
  •  go-up   go-down


67. Contreras CM, Badgwell BD, Askew RL, Feig BW, Cormier JN: Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction. J Clin Oncol; 2009 May 20;27(15_suppl):e20564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction.
  • : e20564 Background: The purpose of this study was to identify clinical and radiographic factors relevant to treatment outcomes in cancer patients presenting with bowel obstruction.
  • RESULTS: Of 194 patients, 25% had a primary diagnosis of colorectal cancer.
  • Computed tomography, plain radiographs, enteral contrast studies, and other modalities were used for diagnosis in 59%, 26%, 12%, and 3% of patients, respectively.
  • Additional relevant clinical factors affecting OS included serum albumin level; however, no association was observed for age, tumor type, site of obstruction, previous bowel obstruction, or abdominal exploration.
  • CONCLUSIONS: Clinical and radiographic factors affect treatment outcomes for cancer patients with bowel obstruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Matuschek C, Bölke E, Gripp S, Budach W, Hermsen D, Peiper M: Mediator release during combined radio chemotherapy in rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):3043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3043 Background: Bacterial translocation is a well-documented phenomenon after polytrauma and major abdominal surgery.
  • Today neoadjuvant chemoradiotherapy is the gold standard for uT3, N+ rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).
  • : 4545 Background: Gastric cancer (GC) with peritoneal metastasis (PM) often complicates ascites or intestinal stenosis and the prognosis is still poor.
  • Anti-cancer drugs generally can not be administered for such patients (pts) due to the risk of serious and prolonged adverse events.
  • Frequencies (%) of grade 4 neutropenia, grade >3 febrile neutropenia, infection with neutropenia, anemia, anorexia, diarrhea, abdominal pain within 6M, and treatment related death (5-FUci/MF) were 0/9, 0/3, 0/5, 10/16, 27/34, 1/10, 5/10 and 2/1, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Santoro J, Yorke E, Rosenzweig K, Goodman K, McNamara J, Pham H, Mageras G: Abstracts. Med Phys; 2010 Jun;37(6Part12):3090-3469

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study compares respiration-correlated kV cone beam CT (RC-kVCBCT) image guidance to standard (uncorrelated) kVCBCT for target localization in radiation treatment of thoracic and abdominal tumors.
  • METHOD AND MATERIALS: In an IRB-approved study, 9 stage II-IV non-small cell lung cancer (NSCLC) patients and 1 stage III stomach tumor patient with fiducials received a respiration-correlated planning CT (RCCT) at simulation and five RC-CBCTs during the first week of treatment.
  • The tumor in each phase of the RC-CBCT is registered to the end-expiration (EE) phase image to obtain the respiration-averaged tumor displacement relative to its EE position.
  • The RCCT and RC-CBCT images at EE are registered to obtain the tumor displacement at the EE position.
  • A vector sum of the three displacements yields the correction to the respiration-averaged tumor position.
  • CONCLUSION: Our preliminary results suggest that for many thoracic and abdominal tumors, position corrections using uncorrelated, respiration-averaged 3D imaging are consistent with those from respiration-correlated imaging; however, respiration-correlated imaging may be indicated for cases of large tumor motion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512987.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Image reconstruction / Lungs / Medical image reconstruction / Medical imaging / Pneumodynamics / Radiation therapy / Radiation treatment
  •  go-up   go-down


71. De La Mota J, Thomas B, Fengwei W, Micaily B, Yajue H, Hernandez E: Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):e16578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC).
  • : e16578 Background: Stage IB1 CC is treated with radical abdominal hysterectomy (RH) and pelvic lymph node dissection (LND) because of presumed risk of parametrial and nodal involvement.
  • Median tumor diameter of patients without lymphovascular space involvement (LVI), with LVI, and with positive LN was 1.2, 2.0, and 2.5 cm respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Hompes D, D'Hoore A, Van Cutsem E, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Kerger J, Legendre H: Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):4101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study.
  • : 4101 Background: Up to 25% of patients with metastatic CRC present with peritoneal carcinomatosis (PC) as the only site of metastases.
  • In 72.9% of patients the primary tumor had been previously resected.
  • Median PCI (peritoneal cancer index) was 11 [1-22], with a median of 6 [1-11] abdominal regions involved and a median lesion size score of 3 [1-3].
  • Complication rate was 52.1%, with 18 intra- and 17 extra-abdominal complications.
  • Occurrence of intra-abdominal complications significantly affected hospital stay (p=0.0012), but no risk factors for occurrence of postoperative complications could be clearly identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Masciari S, Schrader KA, Senz J, Tung N, Balmana J, Razzak AR, Miron P, Huntsman DG, Garber JE: Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration. J Clin Oncol; 2009 May 20;27(15_suppl):11042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration.
  • : 11042 Background: Invasive lobular breast carcinoma (LBC) is part of the hereditary diffuse gastric cancer (HDGC) syndrome, associated with germline mutations in the E-cadherin (CDH1) gene.
  • In this study, we estimated the prevalence of germline CDH1mutations among women with LBC who were either diagnosed at young age or had family history of breast cancer (BC).
  • METHODS: Germline DNA was collected from 383 women with LBC or mixed, lobular/ductal, BC from breast cancer programs, familial cancer clinics, and population-based cohorts.
  • No gastric cancers were reported in these families.
  • Given the difficulty of identifying CDH1 mutations from BC history alone and the importance of managing the gastric cancer risk in CDH1carriers, these findings should underscore the need to obtain an accurate abdominal cancer family history from women with LBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, Khuri SF, Moorman DW: Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol; 2008 Aug;15(8):2164-72
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery.
  • We sought to determine the impact of body mass index (BMI) on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery.
  • METHODS: A prospective, multi-institutional, risk-adjusted cohort study of patients undergoing major intra-abdominal cancer surgery was performed from the 14 university hospitals participating in the Patient Safety in Surgery Study of the National Surgical Quality Improvement Program (NSQIP).
  • Patients were stratified by National Institutes of Health (NIH)-defined BMI obesity class, with 573 (25.4%) patients classified as obese (BMI > 30 kg/m(2)).
  • CONCLUSION: In patients undergoing major intra-abdominal cancer surgery, obesity is not a risk factor for postoperative mortality or major complications.

  • MedlinePlus Health Information. consumer health - Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548313.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Mano M, Hendlisz A, Machiels J, Ehrnrooth E, Aladdin H, Van Laethem J: Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy.
  • In total, 6 patients experienced one or more grade 3/4 toxicities (diarrhea 2; neutropenia 2; leucopenia 1; abdominal pain 1; pulmonary embolism 1; alopecia 1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Pineda C, Cadogan KV, Cadogan MA: Distribution of metastases in NSCLC: Economic impact of imaging. J Clin Oncol; 2009 May 20;27(15_suppl):e19036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that many patients have metastases to several organs, one important question is - "what is the frequency of metastases in the chest, the abdomen, the pelvis, elsewhere?
  • RESULTS: We found that there were 690 metastases to the chest, 205 to the abdomen, 80 to the bones, 18 to the pelvis, 13 to the brain and 23 others, not specified.
  • SEER Cancer Statistics Review, 1975-2005.
  • National Cancer Institute. 03JAN2009. http://seer.cancer.gov/csr/1975_2005/ .].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is active as a single agent and in combination with R in NHL tumor models.
  • Grade 3/4 AEs that occurred in ≥2 pts: nausea 4(17%), vomiting 2(9%), abdominal pain 2(9%), fatigue 2(9%), and small bowel obstruction 2(9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal atrophy secondary to chemoradiation treatment of abdominal malignancies.
  • : e15532 Background: Information on renal atrophy following abdominal chemoradiation (CRT) is limited.
  • METHODS: Patients who received concurrent CRT to the abdomen between 2002 and 2008 were identified for this study to evaluate change in renal size (RS) and function following CRT.
  • RS was defined by craniocaudal measurement on CT images.
  • The primarily irradiated kidney (PK) was defined as the kidney that received the greater mean kidney dose.
  • CONCLUSIONS: Significant detriments in PK size and renal function were seen following abdominal CRT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Kopf A, Bätjer N: [Pain management in gastrointestinal oncology]. Z Gastroenterol; 2005 Sep;43(9):1061-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal cancer is commonly associated with pain needing medical attention.
  • With adequate implementation of therapeutic guidelines into clinical practice including the use of co-analgesics, adjuvants and non-pharmacological treatment options the quality of life of abdominal cancer patients can be considerably improved.
  • [MeSH-major] Abdominal Pain / etiology. Abdominal Pain / prevention & control. Analgesics, Opioid / therapeutic use. Gastrointestinal Neoplasms / complications. Palliative Care / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142615.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  • [Number-of-references] 84
  •  go-up   go-down


80. Kehlet H, Laurberg S: [Gastrointestinal surgery--why specialisation?]. Ugeskr Laeger; 2006 Apr 10;168(15):1519-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nation-wide Danish data have documented a high mortality and long hospital stay after abdominal cancer surgery, which is performed in a large number of departments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640969.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


81. Sakamoto H, Kitano M, Kamata K, Komaki T, Imai H, Chikugo T, Takeyama Y, Kudo M: EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol; 2010 Dec;105(12):2599-606
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Endoscopic ultrasonography (EUS)-guided celiac plexus neurolysis (EUS-CPN) is safe and effective but not beneficial for some patients with extended abdominal cancer.
  • RESULTS: A total of 67 patients with advanced abdominal cancer were included (34 EUS-CPN and 33 EUS-BPN).
  • CONCLUSIONS: Our preliminary data suggested that EUS-BPN using a 25-gauge needle provides patients with advanced abdominal cancer with better pain relief than standard EUS-CPN, and without incurring serious complications.
  • [MeSH-major] Abdominal Neoplasms / complications. Abdominal Pain / etiology. Abdominal Pain / therapy. Autonomic Nerve Block / methods. Celiac Plexus. Endosonography. Needles. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2010 Dec;105(12):2607-9 [21131929.001]
  • (PMID = 20823834.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


82. Quintela-Fandino MA, Young A, Webster S, Grewal M, Wang L, Moore MJ, Krzyzanowska M, Mak TW, Siu LL: Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET). J Clin Oncol; 2009 May 20;27(15_suppl):3526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S doses (mg BID) at cycle 1 were 200 (2 pt)/400 (5)/600 (2)/800 (1); corresponding cycle 1 day 1RAF STC I (%) were 5, 53/94, 100, 95, 16, 65/25, 41/71, respectively (R<sup>2</sup> = 0.13 p = 0.72) Most frequent Gr 3 non-hematologic possibly related adverse events in 30 cycles: hand-foot (2 pt), hypertension, abdominal pain, diarrhea, vomiting, lipase, ileal perforation (1 each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961320.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Yasukawa M, Yasukawa K, Kamiizumi Y, Yokoyama R: Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma. J Anesth; 2007;21(3):420-3
Hazardous Substances Data Bank. Phentolamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma.
  • This case report series describes eight patients (four patients with pancreatic carcinoma, one patient with hepatocellular carcinoma, one patient with gastric and rectal carcinoma, one with sigmoid colon cancer, and one with rectal cancer), whose abdominal cancer pain was treated with intravenous phentolamine infusion at 80 mg x day(-1) for 2 days.
  • All eight patients complained of severe abdominal pain; in five patients the pain radiated to the back, and there was associated anal pain in two patients.
  • [MeSH-major] Abdominal Pain / drug therapy. Analgesics, Non-Narcotic / administration & dosage. Digestive System Neoplasms / complications. Phentolamine / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680199.001).
  • [ISSN] 0913-8668
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; Z468598HBV / Phentolamine
  •  go-up   go-down


84. Borisov DB, Levin AV, Vyl'iurov IV, Sokolov AV, Nedashkovskiĭ EV: [Efficiency of preemptive intravenous paracetamol analgesia in abdominal surgery]. Anesteziol Reanimatol; 2007 Sep-Oct;(5):38-40
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficiency of preemptive intravenous paracetamol analgesia in abdominal surgery].
  • In a randomized, controlled study, 50 patients underwent elective surgery for abdominal cancer lesions under perioperative epidural analgesia.
  • The use of 1 g of paracetamol as a single intravenous preemptive dose in abdominal surgery with perioperative epidural analgesia does not reduce the consumption of the analgesic and the intensity of pain in the postoperative period.

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18051491.001).
  • [ISSN] 0201-7563
  • [Journal-full-title] Anesteziologiia i reanimatologiia
  • [ISO-abbreviation] Anesteziol Reanimatol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


85. Kemer T, Ormen M, Kuralay F, Pehlivan M, Unsal B, Tankurt E: Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions. Tohoku J Exp Med; 2005 Jan;205(1):11-8
MedlinePlus Health Information. consumer health - Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carbohydrate antigen-125 (CA-125) is a tumor marker that has been used for differential diagnosis of peritoneal malignancies.
  • The aim of the present study was to evaluate the diagnostic usefulness of simultaneous quantification of CA-125 in peritoneal fluid and serum for abdominal cancer cases and noncancer diseases.
  • Abdominal cancer group was composed of histologically diagnosed various malignancies (n=10), such as gastric cancer.
  • The sCA-125 levels were significantly higher in noncancer patients than those in the cancer patients, while the pCA-125 levels showed no significant difference between the two groups.
  • Notably, the p/sCA-125 ratio was significantly lower in the noncancer patients than that in the cancer patients.
  • Hence, determination of p/sCA-125 improves the biochemical discrimination of abdominal cancerous cases from noncancerous diseases.
  • [MeSH-major] Ascitic Fluid / immunology. CA-125 Antigen. Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635269.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


86. Sakon M, Kobayashi T, Shimazui T: Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res; 2010 Mar;125(3):e65-70
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.
  • To address this, we evaluated the efficacy and safety of postoperative enoxaparin in Japanese patients undergoing surgery for abdominal cancer.
  • METHODS: This multicenter, open-label study randomized 151 Japanese patients undergoing curative surgery for abdominal cancer to enoxaparin 20mg twice daily for 14 days, started 24-36 hours after surgery (n=113) or intermittent pneumatic compression (IPC) as a reference (n=38).
  • CONCLUSIONS: These favorable efficacy and safety data support the use of enoxaparin (20mg twice daily for 14 days started 24-36 hours after surgery) in Japanese patients undergoing abdominal or pelvic cancer surgery.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Anticoagulants / administration & dosage. Asian Continental Ancestry Group / genetics. Enoxaparin / administration & dosage. Pelvic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19919878.001).
  • [ISSN] 1879-2472
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin
  •  go-up   go-down


87. Schaller C, Penne J, Hornegger J: Time-of-flight sensor for respiratory motion gating. Med Phys; 2008 Jul;35(7Part1):3090-3093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this technical note we present a system that uses time-of-flight (ToF) technology to acquire a real-time multidimensional respiratory signal from a 3D surface reconstruction of the patient's chest and abdomen without the use of markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513021.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4D reconstruction / Biological signal processing / Calibration / Cameras / Emission spectra / Image sensors / Interpolation / Medical imaging / Movement sensors / Pneumodyamics, respiration / Real time information delivery / Time of flight mass spectrometry / Tracking devices / gating / markerless noncontact respiratory tracking / medical signal detection / pneumodynamics / surface reconstruction / time-of-flight
  •  go-up   go-down


88. Senkal M, Geier B, Hannemann M, Deska T, Linseisen J, Wolfram G, Adolph M: Supplementation of Ω-3 Fatty Acids in Parenteral Nutrition Beneficially Alters Phospholipid Fatty Acid Pattern. JPEN J Parenter Enteral Nutr; 2007;31(1):12-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, postoperative parenteral administration of ω-3-PUFA-enriched lipid emulsions could have an impact on the postoperative inflammatory response after abdominal surgery and could be used in standard postoperative care when PN is indicated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28052726.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Gallagher DJ, Milowsky MI, Gerst SR, Tickoo S, Ishill N, Ishill N, Regazzi A, Trout A, Bajorin DF: A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol; 2009 May 20;27(15_suppl):5072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically significant toxicity (Grade 3/4) included: abdominal pain (1), anorexia (1), diarrhea (1), fatigue (4), hand and foot syndrome (2), hemorrhage (2), hypertension (2), mucositis (2), thrombosis (2), and emesis (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Magnan HD, Chou T, LaQuaglia MP, Gerald W, Ladanyi M, Merchant MS: Elevated expression of VEGFR-2 and VEGFA in desmoplastic small round cell tumor (DSRCT) and activity of bevacizumab and irinotecan in a xenograft model of DSRCT. J Clin Oncol; 2009 May 20;27(15_suppl):10016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression of VEGFR-2 and VEGFA in desmoplastic small round cell tumor (DSRCT) and activity of bevacizumab and irinotecan in a xenograft model of DSRCT.
  • : 10016 Background: Desmoplastic small round cell tumor (DSRCT) is an aggressive tumor with poor response to multimodality therapies.
  • METHODS: RNA was extracted from frozen tumor samples (DSRCT, alveolar soft part sarcoma, alveolar rhabdomyosarcoma, synovial sarcoma, and Ewing sarcoma) and a human DSRCT cell line, JN-DSRCT.
  • A primary tumor developed within 8 - 12 weeks with concomitant development of abdominal metastases.
  • Mice were treated during primary tumor growth with bevacizumab (5ug/kg IP weekly), irinotecan (2.5mg/kg IP ×10 days q3 weeks), or a combination of both.
  • RESULTS: Microarray data demonstrated an average of 4.5 times higher RNA expression of VEGFR-2 (KDR) in DSRCT tumor samples as compared to the other translocation-associated sarcomas (p = 3.6 E-12).
  • VEGFA was also highly overexpressed in the DSRCT line and tumor samples when compared to the other translocation-associated sarcomas (2.5 times, p = 1.1E-10).
  • Taken together, the expression data and the sustained response of DSRCT xenografts to bevacizumab suggest that VEGF-dependent angiogenesis is important for DSRCT tumor biology and represents an attractive target for therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962501.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Campos LT, Nemunaitis J, Stephenson J, Richards D, Barve M, Gardner L, Niecestro R, Sportelli P: Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade 3/4 drug-related toxicities > 10% included: abdominal pain (12%), elevated liver enzymes (10%) and fatigue (10%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962225.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Li R, Lewis JH, Cerviño LI, Jiang SB: 4D CT sorting based on patient internal anatomy. Phys Med Biol; 2009 Aug 7;54(15):4821-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Respiratory motion during free-breathing computed tomography (CT) scan may cause significant errors in target definition for tumors in the thorax and upper abdomen.
  • A four-dimensional (4D) CT technique has been widely used for treatment simulation of thoracic and abdominal cancer radiotherapy.
  • The proposed method has been evaluated for ten cancer patients (eight with thoracic cancer and two with abdominal cancer).
  • [MeSH-minor] Abdominal Neoplasms / radiography. Artifacts. Humans. Lung / anatomy & histology. Lung / physiology. Lung / physiopathology. Lung / radiography. Movement. Respiration. Thoracic Neoplasms / radiography. Thorax / physiology. Thorax / physiopathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622855.001).
  • [ISSN] 0031-9155
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Hsiao HL, Shen JT, Yeh HC, Wu WJ, Wang CJ, Huang CH: Intra- and extra-abdominal actinomycosis mimicking urachal tumor in an intrauterine device carrier: a case report. Kaohsiung J Med Sci; 2008 Jan;24(1):35-40
Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra- and extra-abdominal actinomycosis mimicking urachal tumor in an intrauterine device carrier: a case report.
  • In most cases, the diagnosis is made postoperatively because of its unusual clinical presentation.
  • Abdominal actinomycosis is the second most common site of the disease and may mimic abdominal cancer, inflammatory bowel disease or diverticulitis.
  • The abdominal-pelvic form of this disease mostly results from the prolonged use of an intrauterine device.
  • We report a rare case of combined intra- and extra-abdominal actinomycosis mimicking urachal tumor that was diagnosed by computed tomography, which presented as two tender abdominal palpable masses following long-term intrauterine device use.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Wall. Actinomycosis / etiology. Intrauterine Devices / adverse effects. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218568.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


94. Francisco AN, Lobão CA, Sassaki VS, Garbossa MC, Aguiar LR: [Punctate midline myelotomy for the treatment of oncologic visceral pain: analysis of three cases]. Arq Neuropsiquiatr; 2006 Jun;64(2B):446-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mielotomia punctiforme no tratamento da dor oncológica visceral: análise de três casos.
  • METHOD: Three patients with abdominal cancer refractory pain from opiate analgesics were treated by a punctate midline myelotomy through thoracic laminectomy.
  • CONCLUSION: The present report reaffirms the existence of a dorsal column midline pathway related to visceral pain in humans, and its interruption ameliorates abdominal pain due to cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917617.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


95. Mura G, Framarini M, Vagliasindi A, Cavaliere D, Tauceri F, Solfrini G, Milandria C, Verdecchia GM: [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma]. Chir Ital; 2007 Mar-Apr;59(2):217-23
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal carcinomatosis is the first cause of death after surgery for abdominal cancer, with a mean survival of 7 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500178.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


96. Asano T, Takazawa R, Yamato M, Kageyama Y, Kihara K, Okano T: Novel and simple method for isolating autologous mesothelial cells from the tunica vaginalis. BJU Int; 2005 Dec;96(9):1409-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report the development of a new method of isolating autologous mesothelial cells from the tunica vaginalis that are easily obtained and generally free from the effects of abdominal cancer, and to investigate whether transplanting these mesothelial cells is effective in preventing postoperative adhesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287467.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, Gilly FN: [Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy]. Rev Med Interne; 2006 May;27(5):382-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nouveautés thérapeutiques dans la prise en charge des carcinoses péritonéales d'origine digestive: chirurgie de cytoréduction et chimiothérapie intrapéritonéale.
  • PURPOSE: Peritoneal carcinomatosis and particularly those from digestive origin has long been considered as an automatically terminal disease in abdominal cancer patients.
  • It may allow prolonged survival and cure for patients with pseudomyxoma peritonei, peritoneal mesothelioma, carcinomatosis from colorectal or gastric cancer.
  • Qualitative and quantitative prognostic indicators are needed to assess a patient's eligibility, including tumor histopathology, assessment of carcinomatosis extent or completeness of cytoreduction which appears to be the most important.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236392.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. Polati E, Luzzani A, Schweiger V, Finco G, Ischia S: The role of neurolytic celiac plexus block in the treatment of pancreatic cancer pain. Transplant Proc; 2008 May;40(4):1200-4
Hazardous Substances Data Bank. ATROPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of neurolytic celiac plexus block in the treatment of pancreatic cancer pain.
  • Pancreatic carcinoma, an important leading cause of cancer death, has increased steadily in incidence and still has a poor prognosis.
  • Abdominal viscera, including pancreas, liver, gallbladder, adrenal, kidney, and the gastrointestinal tract from the level of the gastroesophageal junction to the splenic flexure of the colon are innervated, at least in part, via the celiac plexus.
  • Although some investigators questioned the role and the efficacy of NCPB in the treatment of upper abdominal cancer pain, most of them have suggested that it may represent the optimal treatment, especially for pancreatic cancer pain.
  • In this report we have reviewed the techniques, results, and complications of NCPB for the treatment of pancreatic cancer pain.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555148.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 7C0697DR9I / Atropine; Y8335394RO / Bupivacaine
  •  go-up   go-down


99. Oei AL, Massuger LF, Oyen WJ: Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm; 2007 Aug;22(4):508-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer.
  • We conducted a single-arm study to determine the biodistribution of intraperitoneally (i.p.) administered 90yttrium-labeled murine monoclonal antibody HMFG1 (90Y-muHMFG1) in patients with advanced stage ovarian cancer.
  • Seventeen (17) patients in complete clinical remission for epithelial ovarian cancer were included.
  • Extraperitoneal leakage was mainly seen in the retroperitoneal spaces covering the upper and lower quadrant of the abdomen.
  • Given the potential attraction of developing i.p. treatments for intra-abdominal cancer, the observations in this study need to be taken into consideration.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Female. Humans. Injections, Intraperitoneal. Neoplasm Staging. Radioimmunotherapy. Time Factors. Treatment Failure. Yttrium Radioisotopes / chemistry. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803445.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / pemtumomab
  •  go-up   go-down


100. Acosta S, Krantz P: Trends in prevalence of fatal surgical diseases at forensic autopsy. ANZ J Surg; 2007 Sep;77(9):718-21
MedlinePlus Health Information. consumer health - Aneurysms.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Deaths referred for forensic autopsy at the Institution of Forensic Medicine, Lund University Hospital, Sweden, between 1970-1982 and 2000-2004, were studied regarding the prevalence of aorto-iliac diseases, acute abdomen and abdominal cancer.
  • The cause-specific mortality ratios in patients with fatal acute abdomen increased significantly from 16.5 (15.1-18.0) to 39.0 (33.2-44.8) per 1000 autopsies, respectively, and there was almost a three-time increase in patients with fatal gastrointestinal haemorrhage and acute alcohol-related pancreatitis.
  • [MeSH-major] Abdomen, Acute / epidemiology. Abdominal Neoplasms / epidemiology. Aneurysm / epidemiology. Autopsy / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2007 Sep;77(9):711 [17685939.001]
  • (PMID = 17685944.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement